Welcome to our dedicated page for Roivant Sciences Ltd. SEC filings (Ticker: ROIV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Roivant Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Roivant Sciences Ltd.'s regulatory disclosures and financial reporting.
Roivant Sciences Ltd. ownership update: Morgan Stanley and Morgan Stanley Investment Management Inc. file an amended Schedule 13G/A reporting beneficial ownership stakes in Roivant common shares. The filing shows 6.9% of the class (Morgan Stanley) and 6.7% (MSIM) with shared voting and dispositive powers disclosed.
The filing attributes specific shared voting power and shared dispositive power amounts to the reporting entities and states the submission is made on behalf of certain operating units collectively described as the "MS Reporting Units." Signature blocks and exhibits (Joint Filing Agreement; Item 7 information) are included.
Roivant Sciences Ltd. ownership amendment: Vivek Ramaswamy reports beneficial ownership of 25,534,970 common shares, representing 3.6% of the outstanding common shares. The percentage is calculated using 715,701,137 shares outstanding as of February 2, 2026. The filing is an Amendment No. 7 to a Schedule 13G/A and is signed by an attorney-in-fact on behalf of Mr. Ramaswamy.
Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an exercise-and-sale transaction in the company’s common shares. He exercised stock options to acquire 200,000 common shares at $3.85 per share and sold 200,000 common shares in open-market transactions at a weighted average price of $29.59 per share, with individual trade prices ranging from $29.33 to $29.88. Following these transactions, he directly holds 1,647,546 common shares. A related stock option award to purchase common shares is described as fully vested.
Pulik Richard reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences CFO Richard Pulik received equity compensation on April 20, 2026. He was granted 60,644 Common Shares as restricted stock units and now holds 297,511 Common Shares directly. He also received 84,026 stock options to buy Common Shares at $29.08 per share, expiring in 2036.
The RSUs vest 25% one year after April 20, 2026, with the rest in twelve equal quarterly installments. The options vest 25% one year after that date, then in thirty-six equal monthly installments, all subject to his continued service.
Roivant Sciences Ltd. reported a compensation-related equity grant to Chief Accounting Officer Jennifer Humes. She received 29,173 Common Share RSUs, bringing her direct Common Share holdings to 113,364 shares after the award.
Humes was also granted 27,157 stock options to buy Common Shares at an exercise price of $29.08 per share, expiring on April 19, 2036. Both the RSUs and options have a vesting commencement date of April 20, 2026 and vest over time, subject to her continuous service with the company.
Roivant Sciences Ltd. director Oren Ilan reported compensation-related share movements. He received an award of 896 Common Shares under the company’s Non-Employee Director Compensation Plan, which was fully vested on the grant date. To cover tax withholding obligations on previously granted shares that vested and settled, 95 Common Shares were withheld and settled on a net basis by the company. Following these transactions, Ilan directly holds 120,229 Common Shares.
Epperly Melissa B, reported acquisition or exercise transactions in this Form 4 filing.
Roivant Sciences Ltd. director Melissa B. Epperly received a grant of 670 Common Shares as equity compensation. The award was made under the company’s Non-Employee Director Compensation Plan and was fully vested on the grant date. Following this grant, she directly holds 16,474 Common Shares.
Roivant Sciences Ltd. director James C. Momtazee reported routine equity compensation activity. He received 469 Common Shares as an award under Roivant’s Non-Employee Director Compensation Plan, which were fully vested on the grant date. To cover related tax withholding obligations, 94 previously granted Common Shares were net-settled back to the company. After these transactions, he directly holds 109,405 Common Shares. These entries reflect compensation and tax withholding mechanics rather than open-market buying or selling.
Roivant Sciences CEO Matthew Gline reported an open-market sale of 289,774 common shares at a weighted average price of $29.16 per share. According to the filing, the trades occurred across multiple transactions between $28.98 and $29.36. After these sales, he directly owns 16,736,116 common shares.
Roivant Sciences Ltd. reported a Form 144 notice for the proposed sale of 200,000 common shares to be sold on 04/20/2026 (method: Options Exercise, grant date 04/20/2022). The filing also shows recent dispositions: 200,000 shares on 02/13/2026, 7,051 shares on 02/20/2026, and 200,000 shares on 04/20/2026, with proceeds listed for each transaction.